MedPath

Effect of omega-3 Fatty acids in addition to Methylphenidate in ADHD

Not Applicable
Not yet recruiting
Conditions
Health Condition 1: F902- Attention-deficit hyperactivity disorder, combined type
Registration Number
CTRI/2020/05/025267
Lead Sponsor
Government Medical College and Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age of the participant between 6-12 years.

2. Children who are willing to give assent and parents/guardians of the participants are willing to give informed consent for participation.

3. School going children

4. Intelligence quotient more than 85

5. Children who have not received Methylphenidate in the past.

Exclusion Criteria

1. Children with Autism Spectrum Disorder.

2. Preexisting structural brain damage and seizures.

3. Presence co-morbid Conduct disorder, Anxiety disorder or Depressive disorder.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the efficacy of omega 3 Fatty acids as an Adjuvant Therapy to Methylphenidate in Attention Deficit Hyperactivity DisorderTimepoint: Baseline, Week 1, Week 2, Week 4, End of week 8, End of Week 12
Secondary Outcome Measures
NameTimeMethod
To study the efficacy of omega 3 Fatty acids as an Adjuvant Therapy to Methylphenidate in Attention Deficit Hyperactivity DisorderTimepoint: Baseline, Week 1, Week 2, Week 4, End of week 8, End of Week 12
© Copyright 2025. All Rights Reserved by MedPath